Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study.

L B A van de Putte; R Rau; F C Breedveld; J R Kalden; M G Malaise; P L C M van Riel; M Schattenkirchner; P Emery; G R Burmester; H Zeidler

doi:10.1136/ard.2003.009563

Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study.

NobleID: NI7P01W66R09S10
Persistent link: https://nobleid.org/ark:/48914/w1/20260515/70FDF351

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/70FDF351.svg?ark=w1%2F20260515%2F70FDF351&value=id)](https://nobleid.org/work/w1/20260515/70FDF351)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study.

NobleID: NI7P01W66R09S10
Persistent link: https://nobleid.org/ark:/48914/w1/20260515/70FDF351

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/70FDF351.svg?ark=w1%2F20260515%2F70FDF351&value=id)](https://nobleid.org/work/w1/20260515/70FDF351)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work